{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:06Z","timestamp":1790719206430,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.vaccine.2009.08.022","type":"journal-article","created":{"date-parts":[[2009,8,26]],"date-time":"2009-08-26T10:13:53Z","timestamp":1251281633000},"page":"6148-6153","source":"Crossref","is-referenced-by-count":15,"title":["Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors"],"prefix":"10.1016","volume":"27","author":[{"given":"Yunzhou","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.08.022_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol Rev"},{"issue":"11","key":"10.1016\/j.vaccine.2009.08.022_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"Botulinum and tetanus neurotoxtins: structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.vaccine.2009.08.022_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.vaccine.2009.08.022_bib4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.addr.2005.01.016","article-title":"Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology","volume":"57","author":"Middlebrook","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2009.08.022_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.08.022_bib6","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.08.022_bib7","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1128\/IAI.66.10.4817-4822.1998","article-title":"Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate","volume":"66","author":"Byrne","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.08.022_bib8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum toxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2009.08.022_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0264-410X(00)00155-9","article-title":"Cloning expression and evaluation sub-unit vaccine against Clostridium type F toxin","volume":"19","author":"Holley","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.022_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.febslet.2004.06.094","article-title":"Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies","volume":"572","author":"Tavallaie","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2009.08.022_bib11","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E","volume":"73","author":"Baldwin","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.08.022_bib12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/IAI.01893-06","article-title":"Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route","volume":"75","author":"Ravichandran","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.08.022_bib13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"A subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.08.022_bib14","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2009.02.091","article-title":"The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.022_bib15","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0264-410X(99)00253-4","article-title":"Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A","volume":"18","author":"Jennifer Clayton","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.022_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02255918","article-title":"DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice","volume":"7","author":"Shyu","year":"2000","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2009.08.022_bib17","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1016\/S0264-410X(03)00260-3","article-title":"DNA vaccination protects against botulinum neurotoxin type F","volume":"21","author":"Bennett","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.022_bib18","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1016\/j.vaccine.2004.04.006","article-title":"Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters","volume":"22","author":"Jathoul","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.022_bib19","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.08.022_bib20","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1016\/j.vaccine.2006.06.004","article-title":"Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice","volume":"24","author":"Lee","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.08.022_bib21","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1016\/j.vaccine.2007.10.016","article-title":"Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A","volume":"25","author":"Yu","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.08.022_bib22","first-page":"365","article-title":"High-level and soluble expressions of botulinum neurotoxin serotype B protective antigen Hc domain in Escherichia coli","volume":"19","author":"Yu","year":"2008","journal-title":"Lett Biotechnol (in Chinese)"},{"issue":"1","key":"10.1016\/j.vaccine.2009.08.022_bib23","first-page":"87","article-title":"High-level expression of foreign genes in vivo and in vitro by improved DNA-based replicon vector derived from Semliki Forest virus","volume":"33","author":"Yu","year":"2006","journal-title":"Prog Biochem Biophys (in Chinese)"},{"issue":"5","key":"10.1016\/j.vaccine.2009.08.022_bib24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1872-2075(07)60052-1","article-title":"Expression of the Hc fargment of Clostridium botulinum neurotoxin serotype A in mammalian cells using recombinant Semliki Forest Virus Expression system","volume":"23","author":"Yu","year":"2007","journal-title":"Chin J Biotech (in Chinese)"},{"issue":"29","key":"10.1016\/j.vaccine.2009.08.022_bib25","doi-asserted-by":"crossref","first-page":"18060","DOI":"10.1074\/jbc.273.29.18060","article-title":"Rapid, high level protein production using DNA-based Semliki Forest virus vectors","volume":"273","author":"DiCiommo","year":"1998","journal-title":"J Bio Chem"},{"issue":"6","key":"10.1016\/j.vaccine.2009.08.022_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cdp.2004.09.004","article-title":"Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene","volume":"28","author":"Ni","year":"2004","journal-title":"Cancer Detection Prev"},{"key":"10.1016\/j.vaccine.2009.08.022_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nbt0698-562","article-title":"Enhancing immune responses using suicidal DNA vaccines","volume":"16","author":"Berglund","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2009.08.022_bib28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/IAI.71.1.575-579.2003","article-title":"Enhanced immunogenicity to mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A","volume":"71","author":"Kirman","year":"2003","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2009.08.022_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1099\/vir.0.80481-0","article-title":"Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1","volume":"86","author":"Nordstrom","year":"2005","journal-title":"J Gen Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2009.08.022_bib30","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09011992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09011992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T19:00:10Z","timestamp":1590087610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09011992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":30,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0264410X09011992"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.08.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}